Navigation Links
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Date:4/18/2011

CRANBURY, N.J., April 18, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley will transition from Chairman and Chief Executive Officer to Executive Chairman in order to devote more time to interests related to public policy, civic service, and philanthropic endeavors. In his role as Executive Chairman, Mr. Crowley will continue to perform his duties as Chairman of the Board of Directors and will advise the current Amicus management team on corporate strategy and the further advancement of the Company's product development pipeline.

"Amicus is in a strong strategic and financial position today as a result of its Phase 3 program in Fabry Disease, a global partnership with GSK Rare Diseases, an exciting pipeline of additional programs, and a dedicated team of employees," said Mr. Crowley. "The management team at Amicus has driven this success to date and the Company is exceptionally well-positioned to advance its vision as a leader in the development of new therapies for rare diseases. In my new role, I look forward to working with the team toward this goal."

"John is an extraordinary leader for Amicus and a champion for the rare disease community," said Donald J. Hayden, Jr., Lead Independent Director of Amicus. "He has developed an outstanding management team at Amicus and we look forward to continuing to work closely with John during his term as Executive Chairman. On behalf of the Board of Directors, I wish John great success."

Matthew R. Patterson, President and Chief Operating Officer of Amicus, has been appointed Acting Chief Executive Officer in addition to his duties as President, effective immediately. The Amicus Board of Directors intends to shortly initiate a search for a full-time Chief Executive Officer and will include Mr. Patterson as a candidate for the position.

"Matt is a proven leader at Amicus
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
2. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
3. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
4. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
5. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
6. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
7. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
8. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
9. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
10. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
11. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Fortune Oil ... officially changed its name to Manzo Pharmaceuticals, Inc. with ... to take effect today, September 17, 2014. Also taking ... The approval is a pivotal event in ... . Mr. Manzo explained, "We could not proceed with ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... 2014 Mindray (NYSE: MR)announced its new generation ... system has been showcased for the first time at ... September, and is scheduled for availability in the U.S. ... the most efficient workhorse in the mid-range segment, the ... perfectly optimized user experience including a gesture-sensitive touch screen, ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
(Date:9/17/2014)... Oxford, UK, September 17, 2014 The International Journal ... has opened up its archive of previously published content: after ... read. A key aim of the IJS is ... hoped that by making these articles available to all will ... Editor-in-Chief of IJS said, "The journal has always ...
(Date:9/17/2014)... WA (PRWEB) September 17, 2014 A ... in fiscal year 2010 revealed 3.2% of these patients developed ... and 2.4% labeled as superficial SSIs. The average difference for ... 876, after adjustments. , The study, conducted by Marin Schweizer, ... the University of Iowa, found the treatment costs for the ...
(Date:9/17/2014)... September 17, 2014 The probability of ... with regular screening and examination, a healthy diet could ... of Epicure with the Chef MDs, renowned ... Paul Rusilko to prepare a delicious Fish Moilee. , ... diets that influence risk of prostate cancer, uncommonly found ...
(Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
(Date:9/17/2014)... September 17, 2014 Kamut International is ... a key ingredient in Michael Angelo’s new “Made With ... new fully organic lasagna ready made, frozen meal. Michael ... pastas and these new products align well with Kamut ... all KAMUT® Brand wheat must be grown certified organic. ...
Breaking Medicine News(10 mins):Health News:Three Ways to Minimize Costs Associated with Surgical Site Infections 2Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2
... A large-scale data review by researchers in China of ... the endoscopic procedure to be safe and effective for ... a pooled detection rate of 68.1 percent for all ... be the most common indication, with a relatively high ...
... cancer patients who use a new combination of the ... Gy) before surgery have an 88 percent chance of ... randomized trial presented at the plenary session, October 3, ... Society for Radiation Oncology (ASTRO). "The results of ...
... 2011) Researchers in Japan have completed a study showing ... pulp can be grafted and produce bone regeneration between parents ... of Cell Transplantation (20:7), now freely ... a number of reasons, and autogenous bone grafting - using ...
... , MONDAY, Sept. 26 (HealthDay News) -- ... inhibitor (SSRI) antidepressants and antiplatelet drugs such as aspirin ... those who take anti-clotting drugs only, a new study ... and Lexapro. Antiplatelet drugs prevent blood cells from ...
... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
... Eating fruits and vegetables may reduce the risk of some ... examined the diets of 918 colorectal cancer patients and 1,021 ... consumption of certain vegetables and fruits were associated with a ... -- that is, the upper and lower portions of the ...
Cached Medicine News:Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 2Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 3Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 4Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells 2Health News:Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients 2Health News:Broccoli, Cabbage, Other Veggies May Protect Against Colon Cancer 2
Touch-Trol Suction Catheter Mini-Tray...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Suction Catheter Kits with Sterile Saline (Bottle)...
Our suction kits include a Tri-Flo® suction catheter, a pop-up solution basin and two sturdy, precuffed latex exam gloves in an inner wallet. Infant and pediatric kits (5/6, 8 and 10 Fr) feature ...
Medicine Products: